The authors describe 12 pregnancies in women with epilepsy using lamotrigine (LTG) monotherapy. A seizure increase in nine pregnancies was probably related to a gradual decline of LTG level-to-dose ratio to 40% of baseline. After delivery, LTG kinetics returned swiftly to baseline, causing toxic side effects in some women. Frequent LTGlevel monitoring and appropriate dose adjustments are advised in the period before and during pregnancy and after delivery, especially in women receiving LTG monotherapy.
The authors describe 12 pregnancies in women with epilepsy using lamotrigine (LTG) monotherapy. A seizure increase in nine pregnancies was probably related to a gradual decline of LTG level-to-dose ratio to 40% of baseline. After delivery, LTG kinetics returned swiftly to baseline, causing toxic side effects in some women. Frequent LTGlevel monitoring and appropriate dose adjustments are advised in the period before and during pregnancy and after delivery, especially in women receiving LTG monotherapy.
COMMENTARY
L amotrigine (LTG) is a popular epilepsy drug for women who are considering becoming pregnant. A commonly held view is that LTG is a safe drug for an expectant mother and has a low rate of teratogenicity (1, 2) . However, are mothers adequately protected from seizures during pregnancy? Seizures are dangerous for the mother and fetus and should be avoided when possible, but especially during pregnancy.
It is well known and has been previously reported by Tran et al. that LTG clearance in pregnant women is increased by >65%, especially in the first trimester (3), causing a sharp decrease in the concentration of the drug. Most of the patients in the Tran study, however, were taking concomitant medications, creating a confounding factor. In the current study by de Haan and colleagues, all nine patients during 12 pregnancies were taking LTG as monotherapy. Therefore the results are important and confirm that an increase in LTG clearance, and not an interaction with another antiepileptic drug (AED), is responsible for the change in blood concentration of LTG during pregnancy. In the de Haan et al. study, seizure aggravation was FIGURE 1. PDR and Package Insert Text for Lamotrigine seen in nine of the 12 pregnancies, with an increase in seizure frequency of >100% in four of them. The reduction in the concentration of LTG decreased to ∼40% of baseline.
Thus women taking LTG who are pregnant will require monitoring of LTG concentrations in the blood, and the dose will need to be appropriately adjusted upward. de Haan et al. observed that patients without the appropriate dose increase experienced an increased risk of seizures at a crucial time, potentially endangering the fetus. Because the pharmacokinetics and clearance of LTG rapidly returns to normal after birth, the dose administered during pregnancy must be almost immediately adjusted to prepregnancy levels. After delivery, the mother may begin to complain of toxic symptoms, such as dizziness, diplopia, and ataxia, if the dose is not rapidly adjusted downward. In this study, side effects were reported 3 to 10 days after delivery. In addition, LTG passes readily into the mother's milk, transferring a high concentration of LTG to the child-≤30% of the mother's plasma level (4, 5) . This effect probably is of no medical consequence, but it is important to follow babies to see if any aberration occurs. For example, because one side effect of LTG is insomnia, it would be valuable to design a study that looked at sleeping patterns of infants being breastfed by mothers on a high dose of LTG.
It is interesting to note that although clearance changes for LTG during pregnancy have been known since 1997 (5), information regarding these changes is still not available in the package insert for LTG and not very explicit in the PDR (see text in Fig. 1) .
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